- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07941453
Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular Hemorrhage (PACT-PCV)
The Added Value of Recombinant Tissue Plasminogen Activator (rtPA) in Pneumatic Displacement of Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy (PCV) With Concomitant Anti-VEGF Therapy: A Prospective Randomized Controlled Trial
The goal of this randomized clinical trial is to determine whether adding recombinant tissue plasminogen activator (rtPA), a clot-dissolving medicine, to gas injection and anti-VEGF treatment improves outcomes in people with submacular hemorrhage (SMH) caused by polypoidal choroidal vasculopathy (PCV).
The main questions it aims to answer are:
- Does adding rtPA increase the proportion of participants with complete displacement of blood from beneath the fovea, the center of the macula, at 1 week after treatment?
- Does adding rtPA improve vision at 6 months and reduce complications, particularly vitreous hemorrhage (bleeding into the gel inside the eye) within 1 month after treatment?
Researchers will compare two pneumatic displacement (PD) strategies: anti-VEGF treatment plus C3F8 gas and rtPA (triple PD) and anti-VEGF treatment plus C3F8 gas without rtPA (dual PD). This comparison will assess the additional benefits and risks of rtPA. The study will enroll 80 participants at a single center. Participants will be randomly assigned to one of the two groups, with an equal chance of receiving either treatment.
The primary outcome is complete SMH displacement at 1 week, defined as no remaining blood beneath the fovea on optical coherence tomography (OCT), a scan that produces detailed images of the retina. Secondary outcomes include changes in best-corrected vision at 6 months, vitreous hemorrhage within 1 month, retinal detachment and other serious complications during follow-up, and the number of anti-VEGF injections over 6 months.
Participants will:
- Undergo baseline eye examinations, vision testing, and retinal imaging.
- Receive injections of anti-VEGF medicine and C3F8 gas into the affected eye, with or without rtPA, according to their assigned group.
- Follow the prescribed face-down positioning instructions for 3 days after treatment.
- Attend follow-up visits at 1 week and at 1, 3, and 6 months after treatment for vision testing, eye examinations, and retinal imaging, and receive further anti-VEGF treatment as needed.
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Fang Zheng
- Número de telefone: +86 18258499106
- E-mail: tjmuzxf@163.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Fovea-involving submacular hemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV), with a hemorrhage area of ≥2 optic disc areas and a subfoveal clot thickness of ≥300 μm.
- An interval of ≤14 days between symptom onset and planned treatment.
- Willingness to participate in the study and provision of written informed consent.
Exclusion Criteria:
- Unwillingness to undergo pneumatic displacement (PD).
- A history of previous SMH.
- Untreated retinal tears, retinal degenerative lesions, or other ocular conditions that make PD unsuitable.
- Concurrent significant vitreous hemorrhage that interferes with postoperative examination and treatment outcome assessment.
- Previous vitrectomy or other ocular surgery that may affect macular structure or the assessment of visual function.
- Coexisting ocular diseases, such as severe cataract, glaucoma, or uveitis, that may interfere with postoperative visual acuity assessment.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Triple PD (Anti-VEGF + Gas + rtPA)
Intravitreal injection of an anti-VEGF agent, intravitreal injection of rtPA (off-label), and intravitreal gas injection for pneumatic displacement. |
Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage. Intravitreal injection of rtPA as an off-label adjunct to pneumatic displacement, administered only in the triple PD arm at the dose specified in the study protocol, to promote clot liquefaction and facilitate submacular hemorrhage displacement. Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms. |
|
Comparador Ativo: Dual PD (Anti-VEGF + Gas)
Intravitreal injection of an anti-VEGF agent and intravitreal gas injection for pneumatic displacement. |
Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage. Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of complete SMH displacement at 1 week after the procedure.
Prazo: 1 week after procedure
|
No residual submacular hemorrhage in the foveal area on OCT. |
1 week after procedure
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of vitreous hemorrhage (VH) and proportion undergoing vitrectomy due to VH within 1 month after the procedure
Prazo: Within 1 month after the procedure
|
Incidence of vitreous hemorrhage within 1 month after the procedure and the proportion of participants requiring pars plana vitrectomy (PPV) because of vitreous hemorrhage. |
Within 1 month after the procedure
|
|
Incidence of severe postoperative complications, including retinal detachment
Prazo: Within 3 months after the procedure
|
Incidence of severe complications after the procedure, including retinal detachment. |
Within 3 months after the procedure
|
|
Change in best-corrected visual acuity (BCVA) at 6 months
Prazo: At 6 months after the procedure
|
Change from baseline in best-corrected visual acuity (BCVA) at 6 months after the procedure, to assess visual prognosis. |
At 6 months after the procedure
|
|
Macular anatomical outcomes at 6 months
Prazo: At 6 months after the procedure
|
Recovery of macular anatomy at 6 months after the procedure, including central macular thickness (CMT) , pigment epithelium detachment (PED) volume, and SMH absorption/resolution, to assess anatomical prognosis. |
At 6 months after the procedure
|
|
Number of anti-VEGF injections within 6 months after the procedure
Prazo: Within 6 months after the procedure
|
Total number of anti-VEGF injections administered within 6 months after the procedure. |
Within 6 months after the procedure
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças oculares
- Doenças uveais
- Doenças da Coróide
- Metaplasia
- Neovascularização de coroide
- Neovascularização Patológica
- Condições Patológicas, Sinais e Sintomas
- Vasculopatia Coroidal Polipoide
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Fatores biológicos
- Hidrolases
- Enzimas
- Enzimas e coenzimas
- Proteínas sanguíneas
- Endopeptidases
- Hidrolases peptídicas
- Serina endopeptidases
- Serina proteases
- Ativadores de plasminogênio
- Fatores de coagulação do sangue
- Ativador de Plasminogênio Tecidual
Outros números de identificação do estudo
- 2 0 2 6 - 0 6 5 2
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .